Michael Eaddy, PharmD, PhD, joined Xcenda in 2001 and, as a Vice President, leads the Real World Evidence consulting practice. Under his leadership, his team helps manufacturers generate evidence-based insights, as well as apply data analytics, to support their products' clinical or economic value propositions.
Dr. Eaddy previously led Xcenda's Strategic Market Insights team where he helped clients gain actionable insights from payers, providers, and patients. He also led more than 50 adherence-based quality and outcomes assessments and completed Markov and Semi-Markov models in oncology. He specializes in advanced statistical techniques with work that includes economic and retrospective analyses, studies assessing the control of unobserved heterogeneity with the use of frailty models, the effects of missing data on the statistical decisions of quality of life data, and the expanded use of the Cochran-Mantel-Haenszel statistic.
Dr. Eaddy brings more than 15 years of experience evaluating, designing, and implementing retrospective analyses using SAS, STATA, and E-views and more than 10 years of experience in the manipulation of large public and private administrative databases. He also has extensive clinical experience in bone marrow transplantation and soft-tissue cancer treatments. Dr. Eaddy has focused much of his research in analyzing outcomes in cardiovascular, urological, and mental health disorders.
He is an active author and speaker and a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), which recognized his work with a best poster award in 2009. Included among his other awards is "best value proposition" as recognized by one of the three largest US pharmaceutical companies. Dr. Eaddy has presented symposia for ISPOR and the Academy of Managed Care Pharmacy, and his work has been published in numerous peer-reviewed journals, including the Journal of Managed Care Pharmacy and the Journal of Clinical Psychopharmacology.
At the University of South Carolina, Dr. Eaddy obtained his BS in Pharmacy, his PharmD, and his PhD in Pharmaceutical and Health Outcomes Sciences.